A Phase 3 interventional study of Apalutamide and LHRH Analogue in Prostate Cancer, sponsored by Alliance Foundation Trials, LLC.. Completed at 69 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Alliance Foundation Trials, LLC. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 11th largest by enrollment, is one of 9 that started in 2017, is one of 16 in phase 3, and was the 20th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
Alliance Foundation Trials, LLC. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Alliance Foundation Trials, LLC. has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Patients will be stratified by PSA doubling time (\< 3 months vs. 3-9 months) and randomized in 1:1:1 fashion to one of three treatment arms: (1) Control arm consisting of LHRH analogue monotherapy (degarelix or leuprolide), (2) Experimental arm consisting of apalutamide in combination with LHRH analogue, and (3) Experimental arm consisting of apalutamide, abiraterone acetate + prednisone, and LHRH analogue. Patients will be treated for a maximum duration of 52 weeks and then enter follow up phase until the time of PSA progression, development of metastasis, or patient withdrawal from study, whichever occurs first. Patients with PSA progression will be followed long term until the development of castration resistance, first metastasis, and death.
The primary endpoint of the study is PSA progression-free survival in the intent-to-treat patient population. PSA progression during the 52-week treatment period is defined as a rising PSA confirmed on repeat measurement, and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during follow up defined as PSA > 0.2 ng/mL confirmed by repeat measurement at least 2 weeks later. Secondary study endpoints include PSA progression-free survival in testosterone-evaluable population, 36-month PSA progression-free survival rate in both intent-to-treat and testosterone-evaluable populations, time to testosterone recovery, time to castration resistance, metastasis-free survival, quality of life, and safety. Each experimental arm will be compared against the control arm in pair-wise fashion. The study is not powered to detect differences in primary or secondary endpoints between the two experimental arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function as defined by the following laboratory values at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive degarelix OR leuprolide with bicalutamide.
Drug: LHRH Analogue
Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
Drug: Apalutamide · Drug: LHRH Analogue
Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
Drug: Apalutamide · Drug: LHRH Analogue · Drug: Abiraterone Acetate · Drug: Prednisone
Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
Also known as: Erleada
Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide. Degarelix: Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles. Leuprolide: Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion: 1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide. OR: 2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.
Also known as: Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide
Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
Also known as: Zytiga
Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
Also known as: Deltasone
PSA Progression-free Survival in the Intent-to-treat Population
To compare PSA progression-free survival in each of the experimental arms (LHRH analogue + apalutamide; LHRH analogue + apalutamide +abiraterone acetate) versus the control arm (LHRH analogue) among all randomized patients (intent-to-treat population). PSA progression-free survival (PSA PFS) is defined as time from date of randomization to date of PSA progression or death, whichever occurs first. PSA progression during the 52-week treatment period defined as a rising PSA confirmed on repeat measurement and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during the follow up phase (post-52 weeks) is defined as the first date of serum PSA \> 0.2 ng/mL, confirmed by repeat measurement at least 2 weeks later.
Time frame: 36 months
PSA Progression-free Survival in the Testosterone-evaluable Population
Compare PSA progression-free survival in testosterone-evaluable population in each experimental arm versus the control arm. Testosterone-evaluable population includes all patients who achieve serum testosterone recovery to \> 50 ng/dL with subsequent PSA measurements sufficient for evaluation
Time frame: 36 months
PSA Progression-free Survival in Both the Intent-to-treat and Testosterone-evaluable Populations
To compare the 36-month PSA progression-free survival rate in each experimental arm versus the control arm in both the intent-to-treat and testosterone-evaluable populations.
Time frame: 36 months
Serum Testosterone
To compare the time to recovery of serum testosterone to greater than 50 ng/dL in each experimental arm versus the control arm.
Time frame: 12 months
Time to Castration Resistance
To compare the time to castration resistance in each experimental arm versus the control arm. The time to castration resistance will be defined as the first date of PSA increase \> 25% and more than 2 ng/mL above nadir with concomitant serum testosterone \< 50 ng/dL.
Time frame: 6 years
Metastasis-Free Survival
To compare metastasis-free survival in each experimental arm versus the control arm.
Time frame: 6 years
Overall Survival
To compare overall survival in each experimental arm versus the control arm.
Time frame: 6 years
Number of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0
To characterize the safety profile in each treatment arm
Time frame: 6 years
Quality of Life Expanded Prostate Cancer Index Composite (EPIC)
Expanded Prostate Cancer Index Composite-26 (EPIC-26), a prostate cancer-specific health-related quality of life instrument. The following domain scores are reported: Bowel (bowel function and bother), Hormonal (hormonal function and bother), Sexual (sexual function and bother), Urinary Incontinence (urinary leakage and associated bother), and Urinary Irritative/Obstructive (urinary frequency, urgency, weak stream, and associated bother). For each domain, scores are transformed to a standardized scale ranging from 0 to 100. A score of 0 represents the worst health-related quality of life and a score of 100 represents the best health-related quality of life for that domain. Higher scores indicate better function, fewer symptoms, and less bother. Domain scores are calculated according to the EPIC-26 scoring algorithm by combining responses from items within each domain and transforming the result to a 0-100 scale.
Time frame: 24 months
Quality of Life Hot Flash Related Daily Interference Scale (HFRDIS)
Hot Flash Related Daily Interference Scale (HFRDIS). Possible range: 0 to 100, with higher scores being worse.
Time frame: 24 months
Quality of Life EQ-5D-5L
EQ-5D-5L Utility based on United States value set. Possible range: -0.573 to 1.000, with higher scores being better. EQ-5D-5L Visual Analog Scale. Possible range: 0 to 100, with higher scores being better.
Time frame: 24 months
Quality of Life PROMIS Fatigue 8a
PROMIS Fatigue 8a T-score. Possible range: 33.1 to 77.8, with higher scores being worse.
Time frame: 24 months
Quality-adjusted PSA Progression-free Survival
To compare the restricted mean quality-adjusted PSA progression-free survival (PSA progression-free survival multiplied by EQ-5D-5L utility score) through 36 months in each experimental arm versus the control arm.
Time frame: 36 months
| Milestone | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Started | 166 | 168 | 169 |
| Completed | 140 | 156 | 148 |
| Not completed | 26 | 12 | 21 |
To compare PSA progression-free survival in each of the experimental arms (LHRH analogue + apalutamide; LHRH analogue + apalutamide +abiraterone acetate) versus the control arm (LHRH analogue) among all randomized patients (intent-to-treat population). PSA progression-free survival (PSA PFS) is defined as time from date of randomization to date of PSA progression or death, whichever occurs first. PSA progression during the 52-week treatment period defined as a rising PSA confirmed on repeat measurement and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during the follow up phase (post-52 weeks) is defined as the first date of serum PSA \> 0.2 ng/mL, confirmed by repeat measurement at least 2 weeks later.
| Months | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| PSA Progression-free Survival in the Intent-to-treat Population | 20.4 (18.9 to 22.5) | 24.7 (23.3 to 26.9) | 27.2 (25.5 to 30.5) |
Compare PSA progression-free survival in testosterone-evaluable population in each experimental arm versus the control arm. Testosterone-evaluable population includes all patients who achieve serum testosterone recovery to \> 50 ng/dL with subsequent PSA measurements sufficient for evaluation
| Months | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| PSA Progression-free Survival in the Testosterone-evaluable Population | 22.1 (20.4 to 25.9) | 25.0 (23.7 to 27.6) | 27.1 (25.4 to 30.9) |
To compare the 36-month PSA progression-free survival rate in each experimental arm versus the control arm in both the intent-to-treat and testosterone-evaluable populations.
| Percentage of Participants | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Intent-to-treat | 17.2 (11.8 to 24.9) | 25.9 (19.8 to 34.0) | 32.1 (25.4 to 40.6) |
| Testosterone-evaluable | 19.8 (13.5 to 29.0) | 26.1 (19.7 to 34.5) | 32.7 (25.7 to 41.6) |
To compare the time to recovery of serum testosterone to greater than 50 ng/dL in each experimental arm versus the control arm.
| Months | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Serum Testosterone | 4.0 (3.7 to 4.8) | 3.9 (3.7 to 4.9) | 4.7 (4.0 to 5.0) |
To compare the time to castration resistance in each experimental arm versus the control arm. The time to castration resistance will be defined as the first date of PSA increase \> 25% and more than 2 ng/mL above nadir with concomitant serum testosterone \< 50 ng/dL.
| Months | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Time to Castration Resistance | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
To compare metastasis-free survival in each experimental arm versus the control arm.
| Months | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Metastasis-Free Survival | 58.5 (44.2 to NA) | 56.3 (50.9 to NA) | 55.5 (51.1 to 76.6) |
To compare overall survival in each experimental arm versus the control arm.
| Participants | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Overall Survival | 148 | 155 | 158 |
To characterize the safety profile in each treatment arm
| Participants | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Number of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0 | 35 | 43 | 68 |
Expanded Prostate Cancer Index Composite-26 (EPIC-26), a prostate cancer-specific health-related quality of life instrument. The following domain scores are reported: Bowel (bowel function and bother), Hormonal (hormonal function and bother), Sexual (sexual function and bother), Urinary Incontinence (urinary leakage and associated bother), and Urinary Irritative/Obstructive (urinary frequency, urgency, weak stream, and associated bother). For each domain, scores are transformed to a standardized scale ranging from 0 to 100. A score of 0 represents the worst health-related quality of life and a score of 100 represents the best health-related quality of life for that domain. Higher scores indicate better function, fewer symptoms, and less bother. Domain scores are calculated according to the EPIC-26 scoring algorithm by combining responses from items within each domain and transforming the result to a 0-100 scale.
| score on a scale | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Bowel: Cycle 1 Day 1 | 92.1977 ± 0.8725 | 95.5881 ± .8577 | 92.9830 ± 0.8462 |
| Bowel: Cycle 7 Day 1 | 92.3285 ± 0.9901 | 92.6867 ± 0.9441 | 92.9257 ± 0.9807 |
| Bowel: End Of Treatment | 91.8436 ± 0.9068 | 93.2766 ± 0.8908 | 93.7399 ± 0.8958 |
| Bowel: 12 Month Followup | 91.8805 ± 1.7080 | 94.0190 ± 1.3187 | 93.6232 ± 1.2485 |
| Hormonal: Cycle 1 Day 1 | 90.8704 ± 0.8801 | 92.6966 ± 0.8600 | 92.4077 ± 0.8541 |
| Hormonal: Cycle 7 Day 1 | 71.9340 ± 1.5878 | 72.4698 ± 1.4982 | 73.7223 ± 1.5470 |
| Hormonal: End Of Treatment | 70.7970 ± 1.6348 | 69.3380 ± 1.5551 | 70.8667 ± 1.5890 |
| Hormonal: !2 Month Followup | 77.0712 ± 2.7085 | 82.7995 ± 2.0509 | 83.3635 ± 1.9303 |
| Sexual: Cycle 1 Day 1 | 30.6812 ± 2.2759 | 30.9818 ± 2.2051 | 29.1073 ± 2.2113 |
| Sexual: Cycle 7 Day 1 | 18.1788 ± 1.5647 | 16.9067 ± 1.4830 | 14.6919 ± 1.5521 |
| Sexual: End Of Treatment | 15.0649 ± 1.3960 | 15.2038 ± 1.3369 | 13.8752 ± 1.3487 |
| Sexual: !2 Month Followup | 22.7586 ± 3.3169 | 28.4695 ± 2.5292 | 22.4491 ± 2.4623 |
| Urinary Incontinence: Cycle 1 Day 1 | 63.3541 ± 2.1618 | 68.9151 ± 2.1197 | 67.7220 ± 2.1106 |
| Urinary Incontinence: Cycle 7 Day 1 | 57.1646 ± 2.2349 | 63.8409 ± 2.1689 | 63.8077 ± 2.2102 |
| Urinary Incontinence: End Of Treatment | 54.7990 ± 2.3081 | 59.5621 ± 2.2490 | 62.3346 ± 2.2668 |
| Urinary Incontinence: 12 Month Followup | 62.5641 ± 3.4609 | 66.0652 ± 2.7235 | 66.0887 ± 2.6035 |
| Urinary Irritative/Obstructive: Cycle 1 Day 1 | 88.3962 ± 1.0877 | 90.0618 ± 1.0653 | 89.7642 ± 1.0557 |
| Urinary Irritative/Obstructive: Cycle 7 Day 1 | 85.6048 ± 1.1022 | 88.4706 ± 1.0561 | 89.5044 ± 1.0865 |
| Urinary Irritative/Obstructive: End Of Treatment | 85.6995 ± 1.2140 | 87.3553 ± 1.1533 | 87.6484 ± 1.1880 |
| Urinary Irritative/Obstructive: 12 Month Followup | 87.8178 ± 2.4371 | 86.8772 ± 1.8182 | 87.4965 ± 1.6848 |
Hot Flash Related Daily Interference Scale (HFRDIS). Possible range: 0 to 100, with higher scores being worse.
| score on a scale | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Cycle 1 Day 1 | 1.3664 ± 0.5752 | 1.8130 ± 0.5494 | 0.9377 ± 0.5464 |
| Cycle 7 Day 1 | 14.4733 ± 1.7323 | 16.9856 ± 1.6676 | 16.0595 ± 1.7506 |
| End Of Treatment | 14.2634 ± 1.8042 | 15.9672 ± 1.7072 | 15.2892 ± 1.7465 |
| 12 Month Followup | 6.7725 ± 2.2614 | 6.2001 ± 1.6731 | 6.1189 ± 1.6167 |
EQ-5D-5L Utility based on United States value set. Possible range: -0.573 to 1.000, with higher scores being better. EQ-5D-5L Visual Analog Scale. Possible range: 0 to 100, with higher scores being better.
| score on a scale | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Visual Analog Scale: Cycle 1 Day 1 | 82.0063 ± 1.0998 | 83.9279 ± 1.0795 | 82.8025 ± 1.0533 |
| Visual Analog Scale: Cycle 7 Day 1 | 80.0568 ± 1.3388 | 80.5834 ± 1.3298 | 80.5332 ± 1.3367 |
| Visual Analog Scale: End Of Treatment | 79.1598 ± 1.2316 | 80.7935 ± 1.1946 | 80.5343 ± 1.1969 |
| Visual Analog Scale:12 Month Followup | 82.0226 ± 2.1342 | 81.2757 ± 1.6028 | 82.5706 ± 1.5280 |
| Utility Score: Cycle 1 Day 1 | 0.8821 ± 0.008298 | 0.9091 ± 0.008063 | 0.9027 ± 0.008105 |
| Utility Score: Cycle 7 Day 1 | 0.8783 ± 0.009412 | 0.8969 ± 0.009002 | 0.8935 ± 0.009346 |
| Utility Score: End Of Treatment | 0.8711 ± 0.009689 | 0.8934 ± 0.009297 | 0.9000 ± 0.009503 |
| Utility Score: 12 Month Followup | 0.8623 ± 0.01649 | 0.8890 ± 0.01291 | 0.8979 ± 0.01229 |
PROMIS Fatigue 8a T-score. Possible range: 33.1 to 77.8, with higher scores being worse.
| score on a scale | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Cycle 1 Day 1 | 44.5051 ± 0.7473 | 43.1027 ± 0.7295 | 43.4506 ± 0.7308 |
| Cycle 7 Day 1 | 49.7267 ± 0.8733 | 50.4765 ± 0.8340 | 50.6559 ± 0.8654 |
| End Of Treatment | 51.4744 ± 0.9394 | 52.1293 ± 0.9020 | 52.1751 ± 0.9169 |
| 12 Month Followup | 48.4949 ± 1.6466 | 47.6405 ± 1.2432 | 46.8446 ± 1.2010 |
To compare the restricted mean quality-adjusted PSA progression-free survival (PSA progression-free survival multiplied by EQ-5D-5L utility score) through 36 months in each experimental arm versus the control arm.
| years | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Quality-adjusted PSA Progression-free Survival | 1.66 (1.56 to 1.76) | 1.97 (1.88 to 2.07) | 2.07 (1.97 to 2.17) |
Collected over Up to 6 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | 18/166 (10.8%) | 14/166 (8.4%) | 154/166 (92.8%) |
| Arm B: Degarelix/Apalutamide | 13/168 (7.7%) | 15/168 (8.9%) | 167/168 (99.4%) |
| Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | 11/169 (6.5%) | 23/169 (13.6%) | 163/169 (96.4%) |
| Event | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| HypertensionVascular disorders | 0/166 | 1/168 | 6/169 |
| SepsisInfections and infestations | 0/166 | 0/168 | 4/169 |
| FallInjury, poisoning and procedural complications | 3/166 | 0/168 | 0/169 |
| Lung infectionInfections and infestations | 0/166 | 0/168 | 3/169 |
| FractureInjury, poisoning and procedural complications | 2/166 | 0/168 | 1/169 |
| Neoplasms benign, mal, uncpec - Oth specNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/166 | 0/168 | 1/169 |
| Gen disord and admin site conds-Oth specGeneral disorders | 0/166 | 2/168 | 0/169 |
| Infections and infestations - Oth specInfections and infestations | 0/166 | 2/168 | 1/169 |
| Non-cardiac chest painGeneral disorders | 0/166 | 0/168 | 2/169 |
| StrokeNervous system disorders | 0/166 | 0/168 | 2/169 |
| Event | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone |
|---|---|---|---|
| Hot flashesVascular disorders | 136/166 | 147/168 | 142/169 |
| FatigueGeneral disorders | 91/166 | 106/168 | 105/169 |
| HypertensionVascular disorders | 42/166 | 54/168 | 65/169 |
| Injection site reactionGeneral disorders | 63/166 | 64/168 | 50/169 |
| AnemiaBlood and lymphatic system disorders | 35/166 | 47/168 | 31/169 |
| InsomniaPsychiatric disorders | 32/166 | 38/168 | 40/169 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 9/166 | 38/168 | 30/169 |
| HyperglycemiaMetabolism and nutrition disorders | 16/166 | 26/168 | 38/169 |
| HeadacheNervous system disorders | 19/166 | 32/168 | 38/169 |
| DiarrheaGastrointestinal disorders | 18/166 | 36/168 | 28/169 |
| Age, Continuous(years) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| Median | 67.2 (60.5 to 71.1) | 66.0 (60.7 to 70.3) | 67.3 (62.4 to 71.3) | 66.7 (61.2 to 71.0) |
| Sex: Female, Male(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 166 | 168 | 169 | 503 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 10 | 7 | 27 |
| Not Hispanic or Latino | 151 | 153 | 156 | 460 |
| Unknown or Not Reported | 5 | 5 | 6 | 16 |
| Race (NIH/OMB)(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 3 |
| Asian | 3 | 0 | 10 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 7 | 13 | 12 | 32 |
| White | 142 | 145 | 136 | 423 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 10 | 8 | 30 |
| Gleason Score Baseline(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| 6-7 | 102 | 102 | 105 | 309 |
| 8 | 15 | 22 | 19 | 56 |
| 9-10 | 49 | 43 | 44 | 136 |
| Missing | 0 | 1 | 1 | 2 |
| Prostate-Specific Antigen (PSA) at study entry(ng/mL) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| Median | 1.7 (1.0 to 3.2) | 1.8 (1.0 to 3.5) | 1.8 (1.0 to 4.2) | 1.8 (1.0 to 3.6) |
| PSA Doubling Time(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| 3 to 9 months | 123 | 125 | 125 | 373 |
| Less than 3 months | 43 | 43 | 44 | 130 |
| N stage(Participants) | Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide | Arm B: Degarelix/Apalutamide | Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone | Total |
|---|---|---|---|---|
| N0 | 127 | 130 | 130 | 387 |
| N1 | 24 | 25 | 23 | 72 |
| NX / Missing | 15 | 13 | 16 | 44 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Jun 2025, 99 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's 99 months is close to that.
Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Alliance Foundation Trials, LLC.